Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 586

1.

Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin.

Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD.

Gastroenterology. 2012 Mar;142(3):562-571.e2. doi: 10.1053/j.gastro.2011.11.026. Epub 2011 Nov 22.

2.

OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.

Ye GD, Sun GB, Jiao P, Chen C, Liu QF, Huang XL, Zhang R, Cai WY, Li SN, Wu JF, Liu YJ, Wu RS, Xie YY, Chan EC, Liou YC, Li BA.

Gastroenterology. 2016 Mar;150(3):659-671.e16. doi: 10.1053/j.gastro.2015.11.041. Epub 2015 Nov 24.

PMID:
26619963
3.

The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC.

Voorneveld PW, Kodach LL, Jacobs RJ, van Noesel CJ, Peppelenbosch MP, Korkmaz KS, Molendijk I, Dekker E, Morreau H, van Pelt GW, Tollenaar RA, Mesker W, Hawinkels LJ, Paauwe M, Verspaget HW, Geraets DT, Hommes DW, Offerhaus GJ, van den Brink GR, Ten Dijke P, Hardwick JC.

Br J Cancer. 2015 Jan 6;112(1):122-30. doi: 10.1038/bjc.2014.560. Epub 2014 Nov 13.

4.

ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.

Shin HW, Choi H, So D, Kim YI, Cho K, Chung HJ, Lee KH, Chun YS, Cho CH, Kang GH, Kim WH, Park JW.

Gastroenterology. 2014 Aug;147(2):430-442.e8. doi: 10.1053/j.gastro.2014.04.047. Epub 2014 May 15.

PMID:
24846398
5.

Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK.

Voorneveld PW, Kodach LL, Jacobs RJ, Liv N, Zonnevylle AC, Hoogenboom JP, Biemond I, Verspaget HW, Hommes DW, de Rooij K, van Noesel CJ, Morreau H, van Wezel T, Offerhaus GJ, van den Brink GR, Peppelenbosch MP, Ten Dijke P, Hardwick JC.

Gastroenterology. 2014 Jul;147(1):196-208.e13. doi: 10.1053/j.gastro.2014.03.052. Epub 2014 Apr 3.

PMID:
24704720
6.

[Expression of Wnt5a, APC, β-catenin and their clinical significance in human colorectal adenocarcinoma].

Cao YC, Yang F, Liu XH, Xin X, Wang CC, Geng M.

Zhonghua Zhong Liu Za Zhi. 2012 Sep;34(9):674-8. doi: 10.3760/cma.j.issn.0253-3766.2012.09.007. Chinese.

PMID:
23159080
7.

Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.

Li L, Li Z, Kong X, Xie D, Jia Z, Jiang W, Cui J, Du Y, Wei D, Huang S, Xie K.

Gastroenterology. 2014 Aug;147(2):485-97.e18. doi: 10.1053/j.gastro.2014.04.048. Epub 2014 May 20.

PMID:
24859161
8.

Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.

Itatani Y, Kawada K, Fujishita T, Kakizaki F, Hirai H, Matsumoto T, Iwamoto M, Inamoto S, Hatano E, Hasegawa S, Maekawa T, Uemoto S, Sakai Y, Taketo MM.

Gastroenterology. 2013 Nov;145(5):1064-1075.e11. doi: 10.1053/j.gastro.2013.07.033. Epub 2013 Jul 25.

PMID:
23891973
9.

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.

Scholer-Dahirel A, Schlabach MR, Loo A, Bagdasarian L, Meyer R, Guo R, Woolfenden S, Yu KK, Markovits J, Killary K, Sonkin D, Yao YM, Warmuth M, Sellers WR, Schlegel R, Stegmeier F, Mosher RE, McLaughlin ME.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17135-40. doi: 10.1073/pnas.1104182108. Epub 2011 Sep 23.

10.

Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.

Zagani R, Hamzaoui N, Cacheux W, de Reyniès A, Terris B, Chaussade S, Romagnolo B, Perret C, Lamarque D.

Gastroenterology. 2009 Oct;137(4):1358-66.e1-3. doi: 10.1053/j.gastro.2009.06.039. Epub 2009 Jun 21.

PMID:
19549529
11.
12.

Antimetastatic role of Smad4 signaling in colorectal cancer.

Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, Datta PK.

Gastroenterology. 2010 Mar;138(3):969-80.e1-3. doi: 10.1053/j.gastro.2009.11.004. Epub 2009 Nov 10.

13.

beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.

Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, Wiesmann M, Garcia PD, Fuller JH, Chan V, Randazzo F, Gundel R, Warren RS, Escobedo J, Aukerman SL, Taylor RN, Fantl WJ.

Cancer Res. 2003 Jun 15;63(12):3145-53.

14.

Beta-catenin/Tcf-4 inhibition after progastrin targeting reduces growth and drives differentiation of intestinal tumors.

Pannequin J, Delaunay N, Buchert M, Surrel F, Bourgaux JF, Ryan J, Boireau S, Coelho J, Pélegrin A, Singh P, Shulkes A, Yim M, Baldwin GS, Pignodel C, Lambeau G, Jay P, Joubert D, Hollande F.

Gastroenterology. 2007 Nov;133(5):1554-68. Epub 2007 Oct 24.

PMID:
17920061
15.

Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells.

Shiou SR, Singh AB, Moorthy K, Datta PK, Washington MK, Beauchamp RD, Dhawan P.

Cancer Res. 2007 Feb 15;67(4):1571-9.

16.

Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis.

Giles RH, Lolkema MP, Snijckers CM, Belderbos M, van der Groep P, Mans DA, van Beest M, van Noort M, Goldschmeding R, van Diest PJ, Clevers H, Voest EE.

Oncogene. 2006 May 18;25(21):3065-70.

PMID:
16407833
17.

Intestinal adenoma formation and MYC activation are regulated by cooperation between MYB and Wnt signaling.

Ciznadija D, Tothill R, Waterman ML, Zhao L, Huynh D, Yu RM, Ernst M, Ishii S, Mantamadiotis T, Gonda TJ, Ramsay RG, Malaterre J.

Cell Death Differ. 2009 Nov;16(11):1530-8. doi: 10.1038/cdd.2009.94. Epub 2009 Jul 17.

18.

HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression.

Li Y, Bavarva JH, Wang Z, Guo J, Qian C, Thibodeau SN, Golemis EA, Liu W.

Oncogene. 2011 Jun 9;30(23):2633-43. doi: 10.1038/onc.2010.632. Epub 2011 Feb 14.

19.

The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.

Kodach LL, Bleuming SA, Peppelenbosch MP, Hommes DW, van den Brink GR, Hardwick JC.

Gastroenterology. 2007 Oct;133(4):1272-81. Epub 2007 Aug 14.

PMID:
17919499
20.

BCL9-2 promotes early stages of intestinal tumor progression.

Brembeck FH, Wiese M, Zatula N, Grigoryan T, Dai Y, Fritzmann J, Birchmeier W.

Gastroenterology. 2011 Oct;141(4):1359-70, 1370.e1-3. doi: 10.1053/j.gastro.2011.06.039. Epub 2011 Jun 23.

PMID:
21703997

Supplemental Content

Support Center